外周血单个核细胞中 基因的改变及其表达与自体造血干细胞移植后多发性骨髓瘤患者的无进展生存期无关。
Genetic Alteration of and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant.
机构信息
Division of Outcomes and Translational Sciences, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.;
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A.
出版信息
Anticancer Res. 2024 Sep;44(9):3771-3776. doi: 10.21873/anticanres.17201.
BACKGROUND/AIM: The tumor suppressor CDKN2C (also designed as p18 or p18) is deleted in approximately 7% to 40% of multiple myeloma (MM) patients, indicative of its potential association with myeloma pathogenesis.
MATERIALS AND METHODS
A quantitative real-time PCR-based assay was developed to determine p18 deletion in DNA from peripheral blood mononuclear cells (PBMCs) in a cohort of 108 multiple myeloma patients after autologous stem cell transplant (ASCT). Additionally, the p18 mRNA expression level in PBMCs was quantitatively assessed using Taqman gene expression assays.
RESULTS
p18 was homozygously and hemizygously deleted in PBMCs from 3 (2.8%) and 5 (4.6%) patients, respectively. Neither the p18 deletion nor the p18 mRNA levels in PBMCs were associated with progression-free survival (PFS), 90-day response, and the occurrence of severe mucositis in these patients (all p-values >0.20).
CONCLUSION
Neither p18 deletion nor p18 mRNA expression in PBMCs can be used as a prognostic biomarker in MM patients.
背景/目的：肿瘤抑制因子 CDKN2C（也称为 p18 或 p18）在大约 7%至 40%的多发性骨髓瘤（MM）患者中缺失，表明其与骨髓瘤发病机制存在潜在关联。
材料和方法
我们开发了一种基于定量实时 PCR 的检测方法，用于确定 108 例接受自体干细胞移植（ASCT）后的多发性骨髓瘤患者外周血单个核细胞（PBMC）中的 p18 缺失。此外，使用 Taqman 基因表达检测法定量评估了 PBMC 中的 p18 mRNA 表达水平。
结果
3 例（2.8%）和 5 例（4.6%）患者的 PBMC 中分别存在 p18 纯合缺失和杂合缺失。在这些患者中，无论是 PBMC 中的 p18 缺失还是 p18 mRNA 水平均与无进展生存期（PFS）、90 天反应以及严重粘膜炎的发生无关（所有 p 值均>0.20）。
结论
在 MM 患者中，PBMC 中的 p18 缺失或 p18 mRNA 表达均不能用作预后生物标志物。
Zotero 插件